Business Context and Reporting Period
X4 Pharmaceuticals, Inc. (XFOR) filed this Form 8-K on November 13, 2023, regarding a regulatory notice received from The Nasdaq Stock Market LLC. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial data point disclosed is the stock price performance triggering the regulatory notice:
- Stock Price Deficiency: The closing bid price of the Company's common stock has remained below the minimum required $1.00 per share for the last 30 consecutive business days.
Material Changes
The material change reported is the receipt of a deficiency letter from Nasdaq citing non-compliance with Listing Rule 5550(a)(2) (the "Bid Price Rule"). This is a status change regarding the Company's listing compliance rather than a change in operational or financial performance.
Outlook, Risks, and Contingencies
Compliance Timeline: The Company has been granted 180 calendar days, until May 13, 2024, to regain compliance. Compliance is achieved if the closing bid price reaches at least $1.00 per share for ten consecutive business days.
Remediation Options: If the Company fails to regain compliance by the initial deadline, it may be eligible for an additional 180-day period. To qualify, it must meet all other initial listing standards (excluding the bid price) and may need to effect a reverse stock split.
Risks: There is no assurance the Company will regain compliance or maintain its listing. If the deficiency is not cured and no additional period is granted, the stock is subject to delisting. The Company may appeal a delisting determination, but success is not guaranteed.
Investor Verification Checklist
- Verify the current closing bid price of XFOR to assess proximity to the $1.00 threshold.
- Monitor Company announcements regarding the potential execution of a reverse stock split.
- Review the Company's cash position in other filings (e.g., 10-Q or 10-K) to determine if it has sufficient liquidity to fund operations while addressing the listing deficiency.
- Check for any subsequent 8-K filings regarding the status of the compliance period or appeals.